Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Yuki Tahata"'
Autor:
Katsuhiko Sato, Hayato Hikita, Minoru Shigekawa, Kazumasa Soma, Ryohei Yamauchi, Jihyun Sung, Seiya Kato, Yoichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto, Kumiko Shirai, Kazuhiro Murai, Yuki Tahata, Teppei Yoshioka, Akira Nishio, Yoshinobu Saito, Takahiro Kodama, Yutaka Sasaki, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Obesity is a risk factor for pancreatic cancer development, partly due to the tissue environment of metabolic disorder-related inflammation. We aimed to detect a tissue environment marker triggered by obesity-related metabolic disorders rela
Externí odkaz:
https://doaj.org/article/8f613e2378b94d819f4f6c55fe410ea1
Autor:
Machiko Kai, Hayato Hikita, Maesaka Kazuki, Yuki Tahata, Kazuma Shinkai, Akira Doi, Kazuyoshi Ohkawa, Masanori Miyazaki, Hisashi Ishida, Kengo Matsumoto, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Naruyasu Kakita, Naoki Morishita, Naoki Hiramatsu, Takeo Usui, Kazuho Imanaka, Yoshinori Doi, Mitsuru Sakakibara, Yuichi Yoshida, Tsugiko Oze, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 19, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/e034304cabb647119278676fe7668d4a
Autor:
Kazuhiro Murai, Takahiro Kodama, Hayato Hikita, Akiyoshi Shimoda, Makoto Fukuoka, Keisuke Fukutomi, Satoshi Shigeno, Yuto Shiode, Daisuke Motooka, Yuichiro Higuchi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Yuki Tahata, Yuki Makino, Ryoko Yamada, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Hepatology Communications, Vol 6, Iss 9, Pp 2474-2487 (2022)
Abstract Current anti–hepatitis B virus (HBV) therapies have little effect on covalently closed circular DNA (cccDNA) and fail to eliminate HBV. The clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system has been reported to
Externí odkaz:
https://doaj.org/article/ca7f46ce603c4fe5827dd0ed21bcf508
Autor:
Hideki Hagiwara, Yoshiki Ito, Takashi Ohta, Yasutoshi Nozaki, Takayuki Iwamoto, Atsushi Hosui, Naoki Hiramatsu, Yuki Tahata, Ryotaro Sakamori, Hayato Hikita, Norio Hayashi
Publikováno v:
JGH Open, Vol 6, Iss 6, Pp 395-401 (2022)
Abstract Background and Aim The development of hepatocarcinogenesis after a sustained virological response (SVR) remains an important issue affecting the balance between treatment and occupational life of workers with chronic hepatitis C virus (HCV)
Externí odkaz:
https://doaj.org/article/aff767c63ad84d4b8396dbd8c2583c83
Autor:
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, Akira Doi, Yuki Tahata, Kazuyoshi Ohkawa, Masahide Oshita, Masanori Miyazaki, Takayuki Yakushijin, Yasutoshi Nozaki, Kengo Matsumoto, Satoshi Tanaka, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Yukinori Yamada, Naoki Morishita, Takeo Usui, Naoki Hiramatsu, Yoshinori Doi, Mitsuru Sakakibara, Kazuho Imanaka, Yuichi Yoshida, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281459 (2023)
AimAlterations in microbial composition of gut microbiota due to antibiotics (ATB) may lead to resistance to immune checkpoint inhibitors (ICIs). This study aimed to assess the impact of ATB use on therapeutic response in patients with hepatocellular
Externí odkaz:
https://doaj.org/article/987d41df248543efad54835c0e7f84eb
Autor:
Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Yuta Myojin, Youichi Sasaki, Shinnosuke Kudo, Kenji Fukumoto, Naoki Mizutani, Yuki Tahata, Yuki Makino, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 5, Pp 1683-1699 (2021)
Background & Aims: Although nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, the role of adipose tissue in NAFLD is not well-understood. Because autophagy has been reported to be involved in the degradation of lipid drople
Externí odkaz:
https://doaj.org/article/6c57edd099aa446b96cd53391b486ebb
Autor:
Kumiko Shirai, Hayato Hikita, Ryotaro Sakamori, Akira Doi, Yuki Tahata, Sadatsugu Sakane, Yoshihiro Kamada, Kazuhiro Murai, Akira Nishio, Ryoko Yamada, Takahiro Kodama, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Naoki Morishita, Kazuho Imanaka, Mitsuru Sakakibara, Tomohide Tatsumi, Eiji Miyoshi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0279416 (2022)
BackgroundPatients with advanced fibrosis are at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C virus (HCV) elimination. We previously reported that serum fucosylated haptoglobin (Fuc-Hp) levels increase as the disease prog
Externí odkaz:
https://doaj.org/article/0c188d920aa749eb89cf660080d4932f
Autor:
Kumiko Shirai, Hayato Hikita, Sadatsugu Sakane, Ryohei Narumi, Jun Adachi, Akira Doi, Satoshi Tanaka, Yuki Tahata, Ryoko Yamada, Takahiro Kodama, Ryotaro Sakamori, Tomohide Tatsumi, Eiji Mita, Takeshi Tomonaga, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 17, Iss 7, p e0271020 (2022)
Extracellular vesicles (EVs) contain proteins, mRNAs, and microRNAs, and their cargos have emerged as novel diagnostic markers in various diseases. We aimed to discover novel and noninvasive biomarkers of liver fibrosis by proteomic analysis using se
Externí odkaz:
https://doaj.org/article/1a72e2ccb2194c868b9b999bc039d29a
Autor:
Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234811 (2020)
BackgroundL31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment.MethodsWe analyzed the frequency of NS5A L31M/V and Y93/H in N
Externí odkaz:
https://doaj.org/article/03a404d7bb3c41b0931f68b59b9a944e
Autor:
Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Naoki Hiramatsu, Yoshinori Doi, Akira Kaneko, Hideki Hagiwara, Yukinori Yamada, Taizo Hijioka, Masami Inada, Shinji Tamura, Yasuharu Imai, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Publikováno v:
Hepatology Communications, Vol 2, Iss 8, Pp 888-896 (2018)
Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first‐line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan. However, the influence of LDV/SOF on the cardiovascular system is poorly
Externí odkaz:
https://doaj.org/article/6628cfc9760b49e591fb8bc5c0f501b9